UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue

Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc. (NASDAQ:VCYT) alongside a price target of $48. Analyst Lu Li retained a favorable outlook after Veracyte’s Q4 testing revenue exceeded expectations, which the company attributed mostly to higher average selling prices and prior-period collections rather than volume growth in Decipher tests.

Veracyte’s 2026 testing revenue projections exceeded street expectations, and the company kept its projected adjusted EBITDA margin of 25%, up from about 21% in 2024, which UBS deems favorable for the stock’s outlook.

The firm also noted potential gains from new product contributions, suggesting that the company’s current revenue projection does not fully account for all growth prospects.

Overall, Veracyte, Inc. (NASDAQ:VCYT) reported preliminary fourth-quarter 2025 revenue of $138-140 million, representing a 16%-18% year-over-year increase that exceeded the consensus forecast of $132 million.

Veracyte, Inc. (NASDAQ:VCYT) is a genomic diagnostics company that develops tests to improve diagnosis and treatment decisions for thyroid, lung, and other cancers, as well as autoimmune diseases.

While we acknowledge the potential of VCYT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.